Geron Corporation
Geron Corporation (GERN) Stock Competitors & Peer Comparison
See (GERN) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GERN | $1.14 | -0.87% | 722.9M | -5.40 | -$0.21 | N/A |
| VRTX | $471.35 | +2.28% | 120.3B | -123.27 | -$3.80 | N/A |
| REGN | $560.87 | +0.40% | 59.2B | 14.18 | $39.36 | +0.31% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $344.32 | +6.01% | 43.1B | -157.40 | -$2.10 | N/A |
| ARGX | $604.77 | +1.61% | 36.6B | 36.44 | $16.43 | N/A |
| BNTX | $111.78 | -0.90% | 26.8B | -29.65 | -$3.76 | N/A |
| RPRX | $37.26 | +0.54% | 21B | 15.21 | $2.45 | +2.30% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $27.08 | -1.37% | 19.9B | -78.65 | -$0.34 | N/A |
Stock Comparison
GERN vs VRTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, VRTX has a market cap of 120.3B. Regarding current trading prices, GERN is priced at $1.14, while VRTX trades at $471.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas VRTX's P/E ratio is -123.27. In terms of profitability, GERN's ROE is -0.48%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, GERN is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check VRTX's competition here
GERN vs REGN Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, REGN has a market cap of 59.2B. Regarding current trading prices, GERN is priced at $1.14, while REGN trades at $560.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas REGN's P/E ratio is 14.18. In terms of profitability, GERN's ROE is -0.48%, compared to REGN's ROE of +0.15%. Regarding short-term risk, GERN is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check REGN's competition here
GERN vs SGEN Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GERN is priced at $1.14, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GERN's ROE is -0.48%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GERN is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check SGEN's competition here
GERN vs ALNY Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ALNY has a market cap of 43.1B. Regarding current trading prices, GERN is priced at $1.14, while ALNY trades at $344.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ALNY's P/E ratio is -157.40. In terms of profitability, GERN's ROE is -0.48%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, GERN is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check ALNY's competition here
GERN vs ARGX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ARGX has a market cap of 36.6B. Regarding current trading prices, GERN is priced at $1.14, while ARGX trades at $604.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ARGX's P/E ratio is 36.44. In terms of profitability, GERN's ROE is -0.48%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, GERN is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ARGX's competition here
GERN vs BNTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, BNTX has a market cap of 26.8B. Regarding current trading prices, GERN is priced at $1.14, while BNTX trades at $111.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas BNTX's P/E ratio is -29.65. In terms of profitability, GERN's ROE is -0.48%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, GERN is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check BNTX's competition here
GERN vs RPRX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RPRX has a market cap of 21B. Regarding current trading prices, GERN is priced at $1.14, while RPRX trades at $37.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RPRX's P/E ratio is 15.21. In terms of profitability, GERN's ROE is -0.48%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, GERN is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RPRX's competition here
GERN vs BGNE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GERN is priced at $1.14, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GERN's ROE is -0.48%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, GERN is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check BGNE's competition here
GERN vs SMMT Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, SMMT has a market cap of 19.9B. Regarding current trading prices, GERN is priced at $1.14, while SMMT trades at $27.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas SMMT's P/E ratio is -78.65. In terms of profitability, GERN's ROE is -0.48%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, GERN is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check SMMT's competition here
GERN vs DNA-WT Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GERN is priced at $1.14, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GERN's ROE is -0.48%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, GERN is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check DNA-WT's competition here
GERN vs INCY Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, INCY has a market cap of 15B. Regarding current trading prices, GERN is priced at $1.14, while INCY trades at $77.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas INCY's P/E ratio is 386.88. In terms of profitability, GERN's ROE is -0.48%, compared to INCY's ROE of +0.34%. Regarding short-term risk, GERN is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check INCY's competition here
GERN vs GMAB Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, GMAB has a market cap of 14.1B. Regarding current trading prices, GERN is priced at $1.14, while GMAB trades at $22.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas GMAB's P/E ratio is 13.45. In terms of profitability, GERN's ROE is -0.48%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, GERN is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check GMAB's competition here
GERN vs UTHR Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, UTHR has a market cap of 13.4B. Regarding current trading prices, GERN is priced at $1.14, while UTHR trades at $287.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas UTHR's P/E ratio is 11.85. In terms of profitability, GERN's ROE is -0.48%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, GERN is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check UTHR's competition here
GERN vs MRNA Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MRNA has a market cap of 12.6B. Regarding current trading prices, GERN is priced at $1.14, while MRNA trades at $32.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MRNA's P/E ratio is -3.74. In terms of profitability, GERN's ROE is -0.48%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, GERN is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check MRNA's competition here
GERN vs KRTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GERN is priced at $1.14, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GERN's ROE is -0.48%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GERN is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check KRTX's competition here
GERN vs BMRN Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, GERN is priced at $1.14, while BMRN trades at $59.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas BMRN's P/E ratio is 21.57. In terms of profitability, GERN's ROE is -0.48%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, GERN is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check BMRN's competition here
GERN vs EXEL Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, EXEL has a market cap of 10.1B. Regarding current trading prices, GERN is priced at $1.14, while EXEL trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas EXEL's P/E ratio is 17.76. In terms of profitability, GERN's ROE is -0.48%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, GERN is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check EXEL's competition here
GERN vs ASND Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ASND has a market cap of 9.9B. Regarding current trading prices, GERN is priced at $1.14, while ASND trades at $167.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ASND's P/E ratio is -24.38. In terms of profitability, GERN's ROE is -0.48%, compared to ASND's ROE of +1.91%. Regarding short-term risk, GERN is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ASND's competition here
GERN vs RXDX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GERN is priced at $1.14, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GERN's ROE is -0.48%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GERN is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RXDX's competition here
GERN vs TECH Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, TECH has a market cap of 9.1B. Regarding current trading prices, GERN is priced at $1.14, while TECH trades at $57.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas TECH's P/E ratio is 69.72. In terms of profitability, GERN's ROE is -0.48%, compared to TECH's ROE of +0.06%. Regarding short-term risk, GERN is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check TECH's competition here
GERN vs VRNA Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, GERN is priced at $1.14, while VRNA trades at $105.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas VRNA's P/E ratio is -52.58. In terms of profitability, GERN's ROE is -0.48%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, GERN is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check VRNA's competition here
GERN vs BBIO Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, BBIO has a market cap of 8.8B. Regarding current trading prices, GERN is priced at $1.14, while BBIO trades at $45.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas BBIO's P/E ratio is -13.01. In terms of profitability, GERN's ROE is -0.48%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, GERN is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check BBIO's competition here
GERN vs IMGN Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GERN is priced at $1.14, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GERN's ROE is -0.48%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, GERN is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check IMGN's competition here
GERN vs BPMC Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GERN is priced at $1.14, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GERN's ROE is -0.48%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, GERN is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check BPMC's competition here
GERN vs CERE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GERN is priced at $1.14, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CERE's P/E ratio is -16.47. In terms of profitability, GERN's ROE is -0.48%, compared to CERE's ROE of -0.43%. Regarding short-term risk, GERN is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check CERE's competition here
GERN vs ROIVW Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, GERN is priced at $1.14, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, GERN's ROE is -0.48%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, GERN is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check ROIVW's competition here
GERN vs ROIV Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, GERN is priced at $1.14, while ROIV trades at $11.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ROIV's P/E ratio is -15.23. In terms of profitability, GERN's ROE is -0.48%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, GERN is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ROIV's competition here
GERN vs HALO Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, HALO has a market cap of 7.3B. Regarding current trading prices, GERN is priced at $1.14, while HALO trades at $59.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas HALO's P/E ratio is 15.70. In terms of profitability, GERN's ROE is -0.48%, compared to HALO's ROE of +1.22%. Regarding short-term risk, GERN is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check HALO's competition here
GERN vs CORT Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CORT has a market cap of 7.2B. Regarding current trading prices, GERN is priced at $1.14, while CORT trades at $69.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CORT's P/E ratio is 59.30. In terms of profitability, GERN's ROE is -0.48%, compared to CORT's ROE of +0.20%. Regarding short-term risk, GERN is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check CORT's competition here
GERN vs JAZZ Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, GERN is priced at $1.14, while JAZZ trades at $116.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas JAZZ's P/E ratio is 15.82. In terms of profitability, GERN's ROE is -0.48%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, GERN is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check JAZZ's competition here
GERN vs RVMD Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, GERN is priced at $1.14, while RVMD trades at $37.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RVMD's P/E ratio is -9.23. In terms of profitability, GERN's ROE is -0.48%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, GERN is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RVMD's competition here
GERN vs IONS Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, GERN is priced at $1.14, while IONS trades at $43.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas IONS's P/E ratio is -13.87. In terms of profitability, GERN's ROE is -0.48%, compared to IONS's ROE of -0.92%. Regarding short-term risk, GERN is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check IONS's competition here
GERN vs RETA Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GERN is priced at $1.14, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RETA's P/E ratio is -66.29. In terms of profitability, GERN's ROE is -0.48%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GERN is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RETA's competition here
GERN vs MDGL Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MDGL has a market cap of 6.5B. Regarding current trading prices, GERN is priced at $1.14, while MDGL trades at $297.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MDGL's P/E ratio is -16.51. In terms of profitability, GERN's ROE is -0.48%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, GERN is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check MDGL's competition here
GERN vs AMRN Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, AMRN has a market cap of 6.1B. Regarding current trading prices, GERN is priced at $1.14, while AMRN trades at $15.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas AMRN's P/E ratio is -3.33. In terms of profitability, GERN's ROE is -0.48%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, GERN is less volatile compared to AMRN. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check AMRN's competition here
GERN vs NUVL Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, NUVL has a market cap of 5.7B. Regarding current trading prices, GERN is priced at $1.14, while NUVL trades at $81.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas NUVL's P/E ratio is -17.92. In terms of profitability, GERN's ROE is -0.48%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, GERN is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check NUVL's competition here
GERN vs RYTM Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, GERN is priced at $1.14, while RYTM trades at $86.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RYTM's P/E ratio is -30.60. In terms of profitability, GERN's ROE is -0.48%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, GERN is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RYTM's competition here
GERN vs TGTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, GERN is priced at $1.14, while TGTX trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas TGTX's P/E ratio is 147.21. In terms of profitability, GERN's ROE is -0.48%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, GERN is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check TGTX's competition here
GERN vs ABCM Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GERN is priced at $1.14, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GERN's ROE is -0.48%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GERN is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ABCM's competition here
GERN vs ISEE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GERN is priced at $1.14, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GERN's ROE is -0.48%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GERN is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ISEE's competition here
GERN vs CRSP Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, GERN is priced at $1.14, while CRSP trades at $59.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CRSP's P/E ratio is -13.14. In terms of profitability, GERN's ROE is -0.48%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, GERN is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check CRSP's competition here
GERN vs AXSM Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, AXSM has a market cap of 4.9B. Regarding current trading prices, GERN is priced at $1.14, while AXSM trades at $103.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas AXSM's P/E ratio is -17.40. In terms of profitability, GERN's ROE is -0.48%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, GERN is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check AXSM's competition here
GERN vs MRUS Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, GERN is priced at $1.14, while MRUS trades at $66.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MRUS's P/E ratio is -15.85. In terms of profitability, GERN's ROE is -0.48%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, GERN is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check MRUS's competition here
GERN vs TLX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, TLX has a market cap of 4.6B. Regarding current trading prices, GERN is priced at $1.14, while TLX trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas TLX's P/E ratio is 134.90. In terms of profitability, GERN's ROE is -0.48%, compared to TLX's ROE of +0.06%. Regarding short-term risk, GERN is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check TLX's competition here
GERN vs PCVX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, PCVX has a market cap of 4.5B. Regarding current trading prices, GERN is priced at $1.14, while PCVX trades at $35.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas PCVX's P/E ratio is -8.69. In terms of profitability, GERN's ROE is -0.48%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, GERN is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check PCVX's competition here
GERN vs ZLAB Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ZLAB has a market cap of 4.5B. Regarding current trading prices, GERN is priced at $1.14, while ZLAB trades at $38.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ZLAB's P/E ratio is -15.58. In terms of profitability, GERN's ROE is -0.48%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, GERN is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check ZLAB's competition here
GERN vs ALPN Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GERN is priced at $1.14, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GERN's ROE is -0.48%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, GERN is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ALPN's competition here
GERN vs ALKS Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ALKS has a market cap of 4.5B. Regarding current trading prices, GERN is priced at $1.14, while ALKS trades at $26.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ALKS's P/E ratio is 12.86. In terms of profitability, GERN's ROE is -0.48%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, GERN is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ALKS's competition here
GERN vs ABVX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ABVX has a market cap of 4.4B. Regarding current trading prices, GERN is priced at $1.14, while ABVX trades at $70.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ABVX's P/E ratio is -20.12. In terms of profitability, GERN's ROE is -0.48%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, GERN is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ABVX's competition here
GERN vs SLNO Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, GERN is priced at $1.14, while SLNO trades at $86.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas SLNO's P/E ratio is -17.72. In terms of profitability, GERN's ROE is -0.48%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, GERN is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check SLNO's competition here
GERN vs KRYS Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, GERN is priced at $1.14, while KRYS trades at $155.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas KRYS's P/E ratio is 36.38. In terms of profitability, GERN's ROE is -0.48%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, GERN is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check KRYS's competition here
GERN vs ADMA Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ADMA has a market cap of 4.4B. Regarding current trading prices, GERN is priced at $1.14, while ADMA trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ADMA's P/E ratio is 21.74. In terms of profitability, GERN's ROE is -0.48%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, GERN is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ADMA's competition here
GERN vs RNA Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RNA has a market cap of 4.3B. Regarding current trading prices, GERN is priced at $1.14, while RNA trades at $38.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RNA's P/E ratio is -11.98. In terms of profitability, GERN's ROE is -0.48%, compared to RNA's ROE of -0.27%. Regarding short-term risk, GERN is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check RNA's competition here
GERN vs CYTK Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CYTK has a market cap of 4.3B. Regarding current trading prices, GERN is priced at $1.14, while CYTK trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CYTK's P/E ratio is -6.79. In terms of profitability, GERN's ROE is -0.48%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, GERN is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check CYTK's competition here
GERN vs OPT Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GERN is priced at $1.14, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas OPT's P/E ratio is -1.52. In terms of profitability, GERN's ROE is -0.48%, compared to OPT's ROE of +2.60%. Regarding short-term risk, GERN is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check OPT's competition here
GERN vs MRTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GERN is priced at $1.14, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GERN's ROE is -0.48%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GERN is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check MRTX's competition here
GERN vs PTCT Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, GERN is priced at $1.14, while PTCT trades at $51.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas PTCT's P/E ratio is 7.57. In terms of profitability, GERN's ROE is -0.48%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, GERN is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check PTCT's competition here
GERN vs MTSR Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MTSR has a market cap of 3.9B. Regarding current trading prices, GERN is priced at $1.14, while MTSR trades at $36.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MTSR's P/E ratio is -14.69. In terms of profitability, GERN's ROE is -0.48%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, GERN is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check MTSR's competition here
GERN vs ACLX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, GERN is priced at $1.14, while ACLX trades at $73.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ACLX's P/E ratio is -23.65. In terms of profitability, GERN's ROE is -0.48%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, GERN is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ACLX's competition here
GERN vs ACAD Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ACAD has a market cap of 3.8B. Regarding current trading prices, GERN is priced at $1.14, while ACAD trades at $23.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ACAD's P/E ratio is 16.53. In terms of profitability, GERN's ROE is -0.48%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, GERN is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check ACAD's competition here
GERN vs AKRO Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, GERN is priced at $1.14, while AKRO trades at $48.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas AKRO's P/E ratio is -12.67. In terms of profitability, GERN's ROE is -0.48%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, GERN is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check AKRO's competition here
GERN vs LEGN Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, LEGN has a market cap of 3.8B. Regarding current trading prices, GERN is priced at $1.14, while LEGN trades at $40.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas LEGN's P/E ratio is -34.55. In terms of profitability, GERN's ROE is -0.48%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, GERN is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check LEGN's competition here
GERN vs RYZB Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GERN is priced at $1.14, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GERN's ROE is -0.48%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GERN is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RYZB's competition here
GERN vs CBAY Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GERN is priced at $1.14, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GERN's ROE is -0.48%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GERN is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check CBAY's competition here
GERN vs AAPG Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, AAPG has a market cap of 3.7B. Regarding current trading prices, GERN is priced at $1.14, while AAPG trades at $38.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas AAPG's P/E ratio is -53.29. In terms of profitability, GERN's ROE is -0.48%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, GERN is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check AAPG's competition here
GERN vs VKTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, GERN is priced at $1.14, while VKTX trades at $34.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas VKTX's P/E ratio is -21.37. In terms of profitability, GERN's ROE is -0.48%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, GERN is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check VKTX's competition here
GERN vs SWTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GERN is priced at $1.14, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GERN's ROE is -0.48%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, GERN is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check SWTX's competition here
GERN vs SRRK Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, GERN is priced at $1.14, while SRRK trades at $38.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas SRRK's P/E ratio is -14.62. In terms of profitability, GERN's ROE is -0.48%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, GERN is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check SRRK's competition here
GERN vs PTGX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, GERN is priced at $1.14, while PTGX trades at $54.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas PTGX's P/E ratio is 70.53. In terms of profitability, GERN's ROE is -0.48%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, GERN is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check PTGX's competition here
GERN vs MLTX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MLTX has a market cap of 3.3B. Regarding current trading prices, GERN is priced at $1.14, while MLTX trades at $50.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MLTX's P/E ratio is -22.76. In terms of profitability, GERN's ROE is -0.48%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, GERN is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check MLTX's competition here
GERN vs KYMR Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, GERN is priced at $1.14, while KYMR trades at $44.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas KYMR's P/E ratio is -14.05. In terms of profitability, GERN's ROE is -0.48%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, GERN is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check KYMR's competition here
GERN vs MORF Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, GERN is priced at $1.14, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MORF's P/E ratio is -14.88. In terms of profitability, GERN's ROE is -0.48%, compared to MORF's ROE of -0.22%. Regarding short-term risk, GERN is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check MORF's competition here
GERN vs MOR Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, GERN is priced at $1.14, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MOR's P/E ratio is -12.64. In terms of profitability, GERN's ROE is -0.48%, compared to MOR's ROE of -1.84%. Regarding short-term risk, GERN is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check MOR's competition here
GERN vs IMVT Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, GERN is priced at $1.14, while IMVT trades at $16.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas IMVT's P/E ratio is -6.10. In terms of profitability, GERN's ROE is -0.48%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, GERN is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check IMVT's competition here
GERN vs CRNX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, GERN is priced at $1.14, while CRNX trades at $29.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CRNX's P/E ratio is -7.69. In terms of profitability, GERN's ROE is -0.48%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, GERN is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check CRNX's competition here
GERN vs KDNY Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, GERN is priced at $1.14, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas KDNY's P/E ratio is -12.47. In terms of profitability, GERN's ROE is -0.48%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, GERN is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check KDNY's competition here
GERN vs MYOV Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, GERN is priced at $1.14, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MYOV's P/E ratio is -14.05. In terms of profitability, GERN's ROE is -0.48%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, GERN is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check MYOV's competition here
GERN vs RARE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, GERN is priced at $1.14, while RARE trades at $28.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RARE's P/E ratio is -4.74. In terms of profitability, GERN's ROE is -0.48%, compared to RARE's ROE of -1.86%. Regarding short-term risk, GERN is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RARE's competition here
GERN vs CPRX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, GERN is priced at $1.14, while CPRX trades at $21.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CPRX's P/E ratio is 13.39. In terms of profitability, GERN's ROE is -0.48%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, GERN is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check CPRX's competition here
GERN vs NAMS Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, NAMS has a market cap of 2.6B. Regarding current trading prices, GERN is priced at $1.14, while NAMS trades at $22.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas NAMS's P/E ratio is -12.38. In terms of profitability, GERN's ROE is -0.48%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, GERN is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check NAMS's competition here
GERN vs LGND Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, LGND has a market cap of 2.5B. Regarding current trading prices, GERN is priced at $1.14, while LGND trades at $137.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas LGND's P/E ratio is -18.05. In terms of profitability, GERN's ROE is -0.48%, compared to LGND's ROE of -0.16%. Regarding short-term risk, GERN is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check LGND's competition here
GERN vs MIRM Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, MIRM has a market cap of 2.5B. Regarding current trading prices, GERN is priced at $1.14, while MIRM trades at $51.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas MIRM's P/E ratio is -31.78. In terms of profitability, GERN's ROE is -0.48%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, GERN is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check MIRM's competition here
GERN vs RXRX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, GERN is priced at $1.14, while RXRX trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas RXRX's P/E ratio is -3.31. In terms of profitability, GERN's ROE is -0.48%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, GERN is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check RXRX's competition here
GERN vs NAMSW Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, NAMSW has a market cap of 2.4B. Regarding current trading prices, GERN is priced at $1.14, while NAMSW trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas NAMSW's P/E ratio is N/A. In terms of profitability, GERN's ROE is -0.48%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, GERN is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check NAMSW's competition here
GERN vs APLS Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, APLS has a market cap of 2.4B. Regarding current trading prices, GERN is priced at $1.14, while APLS trades at $19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas APLS's P/E ratio is -10.53. In terms of profitability, GERN's ROE is -0.48%, compared to APLS's ROE of -1.00%. Regarding short-term risk, GERN is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check APLS's competition here
GERN vs PRVB Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, GERN is priced at $1.14, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas PRVB's P/E ratio is -16.43. In terms of profitability, GERN's ROE is -0.48%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, GERN is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check PRVB's competition here
GERN vs XENE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, GERN is priced at $1.14, while XENE trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas XENE's P/E ratio is -9.59. In terms of profitability, GERN's ROE is -0.48%, compared to XENE's ROE of -0.32%. Regarding short-term risk, GERN is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check XENE's competition here
GERN vs LBPH Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, GERN is priced at $1.14, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas LBPH's P/E ratio is -26.66. In terms of profitability, GERN's ROE is -0.48%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, GERN is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check LBPH's competition here
GERN vs DICE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, GERN is priced at $1.14, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas DICE's P/E ratio is -21.91. In terms of profitability, GERN's ROE is -0.48%, compared to DICE's ROE of +0.56%. Regarding short-term risk, GERN is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check DICE's competition here
GERN vs APGE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, GERN is priced at $1.14, while APGE trades at $38.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas APGE's P/E ratio is -10.51. In terms of profitability, GERN's ROE is -0.48%, compared to APGE's ROE of -0.19%. Regarding short-term risk, GERN is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check APGE's competition here
GERN vs IBRX Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, GERN is priced at $1.14, while IBRX trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas IBRX's P/E ratio is -4.46. In terms of profitability, GERN's ROE is -0.48%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, GERN is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check IBRX's competition here
GERN vs KNSA Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, KNSA has a market cap of 2.2B. Regarding current trading prices, GERN is priced at $1.14, while KNSA trades at $30.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas KNSA's P/E ratio is -126.54. In terms of profitability, GERN's ROE is -0.48%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, GERN is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check KNSA's competition here
GERN vs ARWR Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, GERN is priced at $1.14, while ARWR trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas ARWR's P/E ratio is -12.84. In terms of profitability, GERN's ROE is -0.48%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, GERN is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check ARWR's competition here
GERN vs AGIO Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, GERN is priced at $1.14, while AGIO trades at $38.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas AGIO's P/E ratio is 3.27. In terms of profitability, GERN's ROE is -0.48%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, GERN is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check AGIO's competition here
GERN vs IDYA Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, GERN is priced at $1.14, while IDYA trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas IDYA's P/E ratio is -6.66. In terms of profitability, GERN's ROE is -0.48%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, GERN is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check IDYA's competition here
GERN vs GLPG Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, GERN is priced at $1.14, while GLPG trades at $33.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas GLPG's P/E ratio is -6.36. In terms of profitability, GERN's ROE is -0.48%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, GERN is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check GLPG's competition here
GERN vs CALT Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, GERN is priced at $1.14, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas CALT's P/E ratio is -22.73. In terms of profitability, GERN's ROE is -0.48%, compared to CALT's ROE of -1.67%. Regarding short-term risk, GERN is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for GERN.Check CALT's competition here
GERN vs IRON Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, GERN is priced at $1.14, while IRON trades at $60.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas IRON's P/E ratio is -15.37. In terms of profitability, GERN's ROE is -0.48%, compared to IRON's ROE of -0.23%. Regarding short-term risk, GERN is more volatile compared to IRON. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check IRON's competition here
GERN vs BLTE Comparison July 2025
GERN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GERN stands at 722.9M. In comparison, BLTE has a market cap of 2.1B. Regarding current trading prices, GERN is priced at $1.14, while BLTE trades at $65.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GERN currently has a P/E ratio of -5.40, whereas BLTE's P/E ratio is -46.76. In terms of profitability, GERN's ROE is -0.48%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, GERN is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for GERN.Check BLTE's competition here